Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
The group is persevering with Granite, but funds might be hard to come by.
For $850m up front Roche gets to challenge Pfizer.
First-in-human trial initiations reveal four KRAS assets.